Scalper1 News
Israeli drug giant Teva Pharmaceutical Industries (TEVA) made its long-awaited bid for competitor Mylan on Tuesday, offering $82 a share, or $40.1 billion. Both stocks rose on the news. Teva’s proposal, half cash and half stock, was unsolicited by Mylan (MYL), which adopted a poison-pill provision this month after initial reports of Teva’s interest emerged. On April 8, Mylan made its own unsolicited bid for fellow generic-drug maker Perrigo (PRGO) Scalper1 News
Scalper1 News